p53基因联合化疗治疗喉鳞癌的实验研究

Experimental Study of laryngeal squamous cell carcinoma by p53 gene therapy combined with chemotherapy

目的:研究喉癌细胞系Hep-2中腺病毒介导的p53与顺铂及紫杉醇联合应用在体内及体外的协同效应,指导进一步临床应用。方法:将以腺病毒为载体的p53基因与顺铂及紫杉醇等药物联合应用于喉癌细胞系Hep-2,通过细胞增殖分析,流式细胞仪细胞周期分析,集落形成实验,观察其对喉癌细胞系的作用机制。结果:p53基因联合化疗治疗组肿瘤生长明显受到抑制,肿瘤生长速度显著慢于单纯基因治疗组及单纯化疗治疗组。结论:腺病毒介导的p53基因治疗联合顺铂及紫杉醇的化疗方案可显著提高喉鳞癌的治疗效果。

Objective：To study the laryngeal carcinoma cell line Hep-2 in the adenovirus-mediated p53 gene therapy combined with cisplatin and paclitaxel based chemotherapy in vivo and in vitro synergy.Methods：Used the p53 inserted adenovirus to infect the Hep-2 cell line,combined with cisplatin or paclitaxel co-culture,studied the effect in the ceils by cell reproductive experiment,FCM experiment,and colony formation assay.Results：The growth of cancer cells were inhibited evidently by the p53 gene therapy combined with chemotherapy,the cancer cell growth rate was slower than the control group of pure gene therapy of pure chemotherapy.Conclusion：Adenovirus-mediated p53 gene therapy combined with cisolatin or oaclitaxel based chemotherapy is an effective way to inhibit the growth of cancer.